Medtronic teases new “extravascular” ICD system

Medtronic (NYSE:MDT) today released results from feasibility studies of its new “extravascular” EV-ICD System implantable cardioverter defibrillator designed with leads placed outside the hearts and veins, under the rib cage. The Fridley, Minn.-based medical giant touted results from the studies, which it said are the 1st to explore the novel extravascular placement, as showing the device could provide the “same benefits achieved with conventional ICDs.” Data was presented at the Cardiostim / EHRA Eurospace 2016 conference this week. “Physicians are interested in an ICD with a similar device footprint and performance profile of conventional ICDs – but without the need for vascular access – and these study results are encouraging. We look forward to further assessing the benefits of the EV-ICD approach in order to make this important advancement a reality for physicians and patients worldwide,” Dr. Francis Murgatroyd of London’s King’s College Hospital said in a press release. The in-development system consists of an implanted device, a novel extravascular lead and procedural tools for placement. The EV-ICD system provides life-saving electrical shocks to protect from sudden cardiac death, like conventional ICDs. The company said the device has a lifespan of 10 years, and will help avoid “rare, but potentially serious risks” that can occur by placing leads inside the vasculature and heart. Preliminary data...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Cardiac Assist Devices Cardiac Implants Cardiovascular Medtronic Source Type: news